---
company: Astrana Health, Inc.
ticker: ASTH
form: 8-K
filed: 2026-08-06
accession: 0001104659-26-092003
source: https://www.sec.gov/Archives/edgar/data/1083446/000110465926092003/
---

# Astrana Health (ASTH) earnings release, August 6, 2026

Astrana Health, Inc. (ASTH) · Form 8-K, Item 2.02 · Filed 2026-08-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1083446/000110465926092003/)

Astrana Health, Inc. Reports Second Quarter

2026 Results

Company to Host Conference Call on Thursday,

August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET

ALHAMBRA, Calif.,

August 6, 2026

/PRNewswire/

-- Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”)

(NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the second quarter ended June 30, 2026.

“Our second quarter results reflect the strength of Astrana’s physician-centric, AI-native healthcare operating system and the disciplined execution of our team,” said Brandon Sim, President and Chief Executive Officer of Astrana Health. “We continue to see accelerating demand from both providers and payers for our platform, driving strong growth, record-high adjusted diluted EPS, and robust free cash flow generation. Our performance gives us the confidence to raise our adjusted EBITDA guidance for 2026 even as we reinvest a substantial portion of our first-half outperformance into attractive growth opportunities that we believe will further strengthen our earnings power over time.”

Financial Highlights for Second Quarter Ended June 30, 2026:

All comparisons are to the three months ended

June 30, 2025 unless otherwise stated.

Financial Highlights for Six Months Ended June 30, 2026:

All comparisons are to the six months ended

June 30, 2025 unless otherwise stated.

Recent Operating Highlights

Segment Results for three months ended June 30,

2026:

All comparisons are to the three months ended

June 30, 2025 unless otherwise stated.

* Percentage change of over 500%.

2026 Guidance:

Based on the Company’s existing business, current view of existing market conditions, and assumptions, Astrana is providing the following guidance for total revenue and Adjusted

EBITDA for the three months ending September 30, 2026, updating Adjusted EBITDA guidance for the year ending December 31, 2026, and reaffirming revenue and free cash flow guidance for the year ending December 31, 2026.

See “Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA,” “Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow,” and “Use of Non-GAAP Financial Measures” below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” below for additional information.

Conference Call and Webcast Information:

Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Thursday, August 6,

2026), during which management will discuss the results of the second quarter ended

June 30, 2026. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:

The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=w7Ip0KQB

An accompanying slide presentation will be available in PDF format on the “IR Calendar” page of the Company’s website ( https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana’s current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov.

Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

Note About Consolidated Entities

The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities (“VIEs”) in which the Company is the primary beneficiary. Non-controlling interests represent third party equity ownership interests in the Company’s consolidated entities (including certain VIEs). The amount of net income or loss attributable to non-controlling interests is disclosed in the Company’s consolidated statements of income.

About Astrana Health, Inc.

Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system.

Today, Astrana supports more than 20,000 providers and approximately 1.5 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together,

Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit www.astranahealth.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s guidance for the quarter ending September 30, 2026 and the year ending December 31, 2026, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving... (truncated)ll as long-term value, ability to respond to the changing environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition strategy, and merger integration efforts, as well as statements regarding the material weakness in internal control over financial reporting and the Company’s ability to remediate such material weakness in a timely manner. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the SEC, including, without limitation the risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31,

2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statement made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations investors@astranahealth.com

## Financial statements

### Income Statement (Three Months Ended June 30, 2026 — All comparisons are to the three months ended June 30, 2025 unless otherwise stated. (in thousands))

| | Three Months Ended June 30, 2026 – Care Partners | Three Months Ended June 30, 2026 – Care Delivery | Three Months Ended June 30, 2026 – Care Enablement | Three Months Ended June 30, 2026 – Intersegment Elimination | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2026 – Corporate Costs | Three Months Ended June 30, 2026 – Consolidated Total |
|---|---:|---:|---:|---:|---:|---:|---:|
| Total revenues | 932,836 | 74,696 | 85,598 | -120,610 | ) | $— | 972,520 |
| % change vs. prior year quarter | 48.0% | 95.0% | 109.0% |  |  |  |  |
| Cost of services | 805,469 | 61,923 | 51,665 | -50,559 | ) |  | 868,498 |
| General and administrative expenses | 72,133 | 14,552 | 16,158 | -70,091 | ) | 21,398 | 54,150 |
| Depreciation and amortization | 12,362 | 1,188 | 1,378 |  |  | 622 | 15,550 |
| Total expenses | 889,964 | 77,663 | 69,201 | -120,650 | ) | 22,020 | 938,198 |
| Income (loss) from operations | 42,872 | -2,967 | 16,397 | 40 | -1 | -22,020 | 34,322 |
| % change vs. prior year quarter | -14.0% | -238.0% |  |  |  |  |  |

### Income Statement (Three Months Ending September 30, 2026 (in millions))

| | Three Months Ending September 30, 2026 – Guidance Range – Low | Three Months Ending September 30, 2026 – Guidance Range – High | Year Ending December 31, 2026 – Guidance Range – Low | Year Ending December 31, 2026 – Guidance Range – High |
|---|---:|---:|---:|---:|
| Total revenue | 1,000 | 1,030 | 3,800 | 4,100 |
| Adjusted EBITDA | 72.5 | 77.5 | 255 | 280 |
| Free cash flow |  |  | 105 | 132.5 |

### Income Statement (Three Months Ended June 30, — (UNAUDITED) (in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | Capitation and other revenue, net | 972,520 | 654,808 | 1,937,620 | 1,275,196 |
| Operating expenses | Cost of services, excluding depreciation and amortization | 868,498 | 576,839 | 1,727,855 | 1,125,900 |
| Operating expenses | General and administrative expenses | 54,150 | 50,725 | 115,888 | 94,623 |
| Operating expenses | Depreciation and amortization | 15,550 | 6,904 | 31,028 | 13,752 |
| Operating expenses | Total expenses | 938,198 | 634,468 | 1,874,771 | 1,234,275 |
| Operating expenses | Income from operations | 34,322 | 20,340 | 62,849 | 40,921 |
| Other (expense) income | Income (loss) from equity method investments | 548 | 381 | 2,268 | -486 |
| Other (expense) income | Interest expense | -15,997 | -7,382 | -32,098 | -14,690 |
| Other (expense) income | Interest income | 5,907 | 2,336 | 9,723 | 4,647 |
| Other (expense) income | Unrealized gain (loss) on investments | 4,732 | 14 | 5,816 | -30 |
| Other (expense) income | Other (loss) income | -2,302 | 1,136 | -1,640 | -3,934 |
| Other (expense) income | Total other expense, net | -7,112 | -3,515 | -15,931 | -14,493 |
| Other (expense) income | Income before provision for income taxes | 27,210 | 16,825 | 46,918 | 26,428 |
| Other (expense) income | Provision for income taxes | 8,758 | 6,609 | 15,335 | 9,991 |
| Other (expense) income | Net income | 18,452 | 10,216 | 31,583 | 16,437 |
| Other (expense) income | Net (loss) income attributable to non-controlling interests | -1,287 | 793 | -2,592 | 322 |
| Other (expense) income | Net income attributable to Astrana Health, Inc. | 19,739 | 9,423 | 34,175 | 16,115 |
| Other (expense) income | Earnings per share – basic | 0.4 | 0.19 | 0.7 | 0.33 |
| Other (expense) income | Earnings per share – diluted | 0.4 | 0.19 | 0.69 | 0.33 |
| Other (expense) income | Weighted average shares of common stock outstanding – basic | 49,115,835 | 49,187,885 | 48,986,953 | 48,831,265 |
| Other (expense) income | Weighted average shares of common stock outstanding – diluted | 49,778,028 | 49,470,677 | 49,418,278 | 49,162,653 |

### Income Statement (Three Months Ended June 30, (in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, | Three Months Ended June 30, – 2025 |  | Six Months Ended June 30, – 2026 | Six Months Ended June 30, | Six Months Ended June 30, – 2025 |  |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Net income | 18,452 |  | 10,216 |  | 31,583 |  | 16,437 |  |
| Interest expense | 15,997 |  | 7,382 |  | 32,098 |  | 14,690 |  |
| Interest income | -5,907 | ) | -2,336 | ) | -9,723 | ) | -4,647 | ) |
| Provision for income taxes | 8,758 |  | 6,609 |  | 15,335 |  | 9,991 |  |
| Depreciation and amortization | 15,550 |  | 6,904 |  | 31,028 |  | 13,752 |  |
| EBITDA | 52,850 |  | 28,775 |  | 100,321 |  | 50,223 |  |
| (Income) loss from equity method investments | -548 | ) | -381 | ) | -2,268 | ) | 486 |  |
| Other, net | 4,800 | -1 | 7,998 | -2 | 15,450 | -3 | 14,257 | -4 |
| Stock-based compensation | 11,787 |  | 11,709 |  | 21,682 |  | 19,519 |  |
| Adjusted EBITDA | 68,889 |  | 48,101 |  | 135,185 |  | 84,485 |  |
| Total revenue | 972,520 |  | 654,808 |  | 1,937,620 |  | 1,275,196 |  |
| Adjusted EBITDA margin | 7 | % | 7 | % | 7 | % | 7 | % |

### Income Statement (Three Months Ended June 30, (in thousands, except for share and per share data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, | Three Months Ended June 30, – 2025 |  | Six Months Ended June 30, – 2026 | Six Months Ended June 30, | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|---:|---:|---:|
| Net income | 18,452 |  | 10,216 |  | 31,583 |  | 16,437 |
| (Income) loss from equity method investments | -548 | ) | -381 | ) | -2,268 | ) | 486 |
| Other, net (1) | 4,800 |  | 7,998 |  | 15,450 |  | 14,257 |
| Stock-based compensation | 11,787 |  | 11,709 |  | 21,682 |  | 19,519 |
| Amortization of intangible assets attributable to acquisitions | 13,806 |  | 6,179 |  | 27,656 |  | 12,442 |
| Tax adjustments | -5,965 | -2 | -4,637 | -3 | -13,490 | -2 | -9,238 |
| Adjusted net income attributable to non-controlling interests | -2,561 | -4 | -3,715 | -5 | -4,489 | -4 | -6,032 |
| Adjusted net income attributable to Astrana Health, Inc. | 39,771 |  | 27,369 |  | 76,124 |  | 47,871 |
| Weighted average shares of common stock outstanding – diluted | 49,778,028 |  | 49,470,677 |  | 49,418,278 |  | 49,162,653 |

### Income Statement (Year Ending December 31, 2026 — Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA (in thousands))

| | Year Ending December 31, 2026 – Guidance Range – Low | Year Ending December 31, 2026 – Guidance Range – High |
|---|---:|---:|
| Net income | 59,000 | 74,000 |
| Interest expense | 49,000 | 53,000 |
| Provision for income taxes | 38,000 | 44,000 |
| Depreciation and amortization | 65,000 | 65,000 |
| EBITDA | 211,000 | 236,000 |
| Income from equity method investments | -4,000 | -4,000 |
| Other, net | 9,000 | 9,000 |
| Stock-based compensation | 39,000 | 39,000 |
| Adjusted EBITDA | 255,000 | 280,000 |

### Balance Sheet (June 30, 2026 — (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA))

| | June 30, 2026 – (Unaudited) | December 31, 2025 |
|---|---:|---:|
| Current assets | Cash and cash equivalents | 400,792 | 429,474 |
| Current assets | Receivables, net (including amounts from related parties) | 465,080 | 374,465 |
| Current assets | Income taxes receivable |  | 1,799 |
| Current assets | Other receivables | 24,113 | 26,385 |
| Current assets | Prepaid expenses and other current assets | 25,857 | 26,264 |
| Current assets | Loans receivable | 3,318 | 4,926 |
| Current assets | Total current assets | 919,160 | 863,313 |
| Non-current assets | Property and equipment, net | 62,567 | 57,332 |
| Non-current assets | Intangible assets, net | 243,312 | 270,968 |
| Non-current assets | Goodwill | 886,995 | 865,305 |
| Non-current assets | Income taxes receivable, net of current portion | 26,220 | 26,220 |
| Non-current assets | Loans receivable, net of current portion | 49,273 | 48,724 |
| Non-current assets | Investments in other entities – equity method | 27,805 | 25,637 |
| Non-current assets | Operating lease right-of-use assets | 39,194 | 35,738 |
| Non-current assets | Other assets | 27,554 | 25,424 |
| Non-current assets | Total non-current assets | 1,362,920 | 1,355,348 |
| Non-current assets | Total assets (1) | 2,282,080 | 2,218,661 |
| Current liabilities | Accounts payable and accrued expenses | 245,860 | 195,912 |
| Current liabilities | Fiduciary accounts payable | 3,771 | 3,524 |
| Current liabilities | Income taxes payable | 2,082 |  |
| Current liabilities | Medical liabilities | 415,765 | 335,705 |
| Current liabilities | Operating lease liabilities | 8,938 | 7,809 |
| Current liabilities | Current portion of long-term debt | 53,848 | 47,865 |
| Current liabilities | Other liabilities | 17,375 | 24,458 |
| Current liabilities | Total current liabilities | 747,639 | 615,273 |
| Non-current liabilities | Deferred tax liability | 8,795 | 5,491 |
| Non-current liabilities | Operating lease liabilities, net of current portion | 33,975 | 31,552 |
| Non-current liabilities | Long-term debt, net of current portion and deferred financing costs | 882,650 | 990,904 |
| Non-current liabilities | Other long-term liabilities | 10,442 | 17,107 |
| Non-current liabilities | Total non-current liabilities | 935,862 | 1,045,054 |
| Non-current liabilities | Total liabilities (1) | 1,683,501 | 1,660,327 |
| Mezzanine deficit | Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation (“APC”) | -242,261 | -234,962 |
| Stockholders’ equity | Common stock, $0.001 par value per share; 100,000,000 shares authorized, 49,226,943 and 48,885,358 shares issued and outstanding, excluding 10,695,758 and 10,571,011 treasury shares, as of June 30, 2026 and December 31, 2025, respectively | 49 | 49 |
| Stockholders’ equity | Additional paid-in capital | 487,820 | 470,863 |
| Stockholders’ equity | Retained earnings | 342,355 | 308,379 |
| Stockholders’ equity | Total stockholders’ equity | 830,224 | 779,291 |
| Stockholders’ equity | Non-controlling interests | 10,616 | 14,005 |
| Stockholders’ equity | Total equity | 840,840 | 793,296 |
| Stockholders’ equity | Total liabilities, mezzanine deficit, and stockholders’ equity | 2,282,080 | 2,218,661 |

### Cash Flow (Six Months Ended June 30, — (UNAUDITED) (in thousands))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|
| Cash flows from operating activities | Net income | 31,583 |  | 16,437 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation and amortization | 31,028 |  | 13,752 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization of debt issuance cost | 2,280 |  | 1,740 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Share-based compensation | 21,682 |  | 19,519 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Non-cash lease expense | 4,131 |  | 2,559 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Deferred tax | 2,734 |  | -1,961 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Change in fair value of contingent consideration liabilities | -4,820 | ) | 3,351 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Other | -6,735 | ) | 560 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Changes in operating assets and liabilities, net of business combinations | 18,921 |  | 51,571 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Net cash provided by operating activities | 100,804 |  | 107,528 |
| Cash flows from investing activities | Payments for business and assets acquisition, net of cash acquired | -3,739 | ) |  |
| Cash flows from investing activities | Purchases of property and equipment | -7,878 | ) | -4,490 |
| Cash flows from investing activities | Other | 2,545 |  | 1,019 |
| Cash flows from investing activities | Net cash used in investing activities | -9,072 | ) | -3,471 |
| Cash flows from financing activities | Dividends paid | -199 | ) | -6,233 |
| Cash flows from financing activities | Borrowings on debt |  |  | 412,000 |
| Cash flows from financing activities | Repayment of debt | -103,933 | ) | -431,357 |
| Cash flows from financing activities | Deferred financing cost |  |  | -17,241 |

### Cash Flow (Six Months Ended June 30, — Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (in thousands))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| Net cash provided by operating activities | 100,804 | 107,528 |
| Purchases of property and equipment | -7,878 | -4,490 |
| Free cash flow | 92,926 | 103,038 |

### Cash Flow (Year Ending December 31, 2026 — Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (in thousands))

| | Year Ending December 31, 2026 – Guidance Range – Low | Year Ending December 31, 2026 – Guidance Range – High |
|---|---:|---:|
| Net cash provided by operating activities | 125,000 | 145,000 |
| Cash used in purchases of property and equipment | -20,000 | -12,500 |
| Free cash flow | 105,000 | 132,500 |
